SG11201911598WA - Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis - Google Patents
Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosisInfo
- Publication number
- SG11201911598WA SG11201911598WA SG11201911598WA SG11201911598WA SG11201911598WA SG 11201911598W A SG11201911598W A SG 11201911598WA SG 11201911598W A SG11201911598W A SG 11201911598WA SG 11201911598W A SG11201911598W A SG 11201911598WA SG 11201911598W A SG11201911598W A SG 11201911598WA
- Authority
- SG
- Singapore
- Prior art keywords
- endometriosis
- gonadotropin
- treatment
- releasing hormone
- dosing regimens
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762515268P | 2017-06-05 | 2017-06-05 | |
PCT/EP2018/064768 WO2018224498A1 (en) | 2017-06-05 | 2018-06-05 | Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201911598WA true SG11201911598WA (en) | 2020-01-30 |
Family
ID=62620835
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201911598WA SG11201911598WA (en) | 2017-06-05 | 2018-06-05 | Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP3634418A1 (en) |
JP (2) | JP7348171B2 (en) |
KR (1) | KR20200027481A (en) |
CN (1) | CN110996956A (en) |
AU (2) | AU2018280742B2 (en) |
CA (1) | CA3066190A1 (en) |
EA (1) | EA201992612A1 (en) |
MA (1) | MA49256A (en) |
MX (1) | MX2019014483A (en) |
SG (1) | SG11201911598WA (en) |
WO (1) | WO2018224498A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2019014482A (en) | 2017-06-05 | 2020-08-17 | ObsEva SA | Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss. |
CA3148939A1 (en) * | 2019-08-08 | 2021-02-11 | ObsEva S.A. | Compositions and methods for the treatment of estrogen-dependent disorders |
CN113384581B (en) * | 2020-03-12 | 2023-11-14 | 成都倍特药业股份有限公司 | Pharmaceutical composition comprising gonadotrophin releasing hormone antagonist |
EP4243829A1 (en) * | 2020-11-11 | 2023-09-20 | Myovant Sciences GmbH | Methods of administering relugolix |
CN115232144B (en) * | 2021-04-22 | 2024-04-02 | 长春金赛药业有限责任公司 | Nitrogen-containing condensed ring derivative, pharmaceutical composition, and preparation method and application thereof |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5342760A (en) | 1992-06-10 | 1994-08-30 | Abbott Laboratories | Determination of estradiol by competitive immunoassay |
US5663054A (en) | 1995-03-03 | 1997-09-02 | Abbott Laboratories | Determination of steroids by competitive immunoassay |
PL360294A1 (en) | 2000-07-05 | 2004-09-06 | Yamanouchi Pharmaceutical Co.Ltd. | Propane-1,3-dione derivatives |
US7300935B2 (en) | 2003-01-29 | 2007-11-27 | Takeda Pharmaceutical Company | Thienopyrimidine compounds and use thereof |
BRPI0412314B8 (en) | 2003-07-07 | 2021-05-25 | Neurocrine Biosciences Inc | compound 3-[2(r)-{hydroxycarbonylpropyl-amino}-2-phenylethyl]-5-(2-fluoro-3-methoxyphenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methyl -pyrimidine-2,4(1h,3h)-dione, pharmaceutical composition comprising said compound and its use for the treatment of a condition related to sex hormone |
CA2603185C (en) | 2005-03-31 | 2011-07-26 | Astellas Pharma Inc. | Propane-1,3-dione derivative or salt thereof |
ES2398917T7 (en) | 2005-10-19 | 2022-10-26 | Kissei Pharmaceutical | Condensed heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof |
WO2009062087A1 (en) | 2007-11-07 | 2009-05-14 | Neurocrine Biosciences, Inc. | Processes for the preparation of uracil derivatives |
SG183243A1 (en) | 2010-02-10 | 2012-09-27 | Kissei Pharmaceutical | Salt of fused heterocyclic derivative and crystal thereof |
SG11201403749VA (en) | 2012-01-16 | 2014-07-30 | Bayer Ip Gmbh | Spiroindoline derivatives as gonadotropin- releasing hormone receptor antagonists |
WO2013126517A1 (en) | 2012-02-21 | 2013-08-29 | Northwestern University | Anti-mullerian hormone detection in whole blood |
CA2883126A1 (en) | 2012-09-07 | 2014-03-13 | Astellas Pharma Inc. | Method for producing sulfonyl amidine compound |
WO2014042176A1 (en) | 2012-09-14 | 2014-03-20 | キッセイ薬品工業株式会社 | Method for producing fused-heterocyclic derivative, and production intermediate thereof |
LT2900675T (en) | 2012-09-28 | 2019-05-27 | Takeda Pharmaceutical Company Limited | Production method of thienopyrimidine derivative |
US10881659B2 (en) | 2013-03-15 | 2021-01-05 | Abbvie Inc. | Methods of treating heavy menstrual bleeding |
AR095785A1 (en) | 2013-04-09 | 2015-11-11 | Bayer Pharma AG | DERIVATIVES OF SPIROINDOLINE AND PHARMACEUTICAL COMPOSITIONS OF THE SAME |
CA3002791A1 (en) | 2015-09-01 | 2017-03-09 | Abbvie Inc. | Methods of administering elagolix |
EP3498280B1 (en) * | 2016-08-08 | 2024-04-03 | Kissei Pharmaceutical Co., Ltd. | Administration and dosage of therapeutic agent for endometriosis |
-
2018
- 2018-06-05 AU AU2018280742A patent/AU2018280742B2/en active Active
- 2018-06-05 CN CN201880050650.3A patent/CN110996956A/en active Pending
- 2018-06-05 EA EA201992612A patent/EA201992612A1/en unknown
- 2018-06-05 MA MA049256A patent/MA49256A/en unknown
- 2018-06-05 WO PCT/EP2018/064768 patent/WO2018224498A1/en unknown
- 2018-06-05 KR KR1020197038977A patent/KR20200027481A/en not_active Application Discontinuation
- 2018-06-05 SG SG11201911598WA patent/SG11201911598WA/en unknown
- 2018-06-05 JP JP2020516959A patent/JP7348171B2/en active Active
- 2018-06-05 EP EP18731378.8A patent/EP3634418A1/en active Pending
- 2018-06-05 MX MX2019014483A patent/MX2019014483A/en unknown
- 2018-06-05 CA CA3066190A patent/CA3066190A1/en active Pending
-
2023
- 2023-05-23 JP JP2023084336A patent/JP2023113715A/en active Pending
-
2024
- 2024-03-14 AU AU2024201701A patent/AU2024201701A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN110996956A (en) | 2020-04-10 |
AU2024201701A1 (en) | 2024-04-04 |
JP7348171B2 (en) | 2023-09-20 |
AU2018280742A1 (en) | 2020-01-30 |
EA201992612A1 (en) | 2020-05-20 |
EP3634418A1 (en) | 2020-04-15 |
JP2023113715A (en) | 2023-08-16 |
KR20200027481A (en) | 2020-03-12 |
MA49256A (en) | 2021-05-26 |
MX2019014483A (en) | 2020-08-17 |
AU2018280742B2 (en) | 2023-12-21 |
JP2020522571A (en) | 2020-07-30 |
WO2018224498A1 (en) | 2018-12-13 |
CA3066190A1 (en) | 2018-12-13 |
US20200138819A1 (en) | 2020-05-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL272069A (en) | Dosage regimens of anti-lag-3 antibodies and uses thereof | |
SG11201911598WA (en) | Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis | |
IL271222A (en) | Dosage regimens for anti-tim-3 antibodies and uses thereof | |
HUE055109T2 (en) | Dosing regimens for anti-tf-antibody drug-conjugates | |
GB201713653D0 (en) | Dosage regimen | |
ZA201900777B (en) | Usage and dosage of therapeutic agents for endometriosis | |
IL253247B (en) | Dosage regimen for madcam antagonists | |
HK1259307A1 (en) | Dosing regimens | |
IL272864A (en) | Il-33 antagonist-containing therapeutic agent for endometriosis | |
GB201521217D0 (en) | Dosage regimens | |
IL275238A (en) | Liquid composition comprising vegf antagonist | |
IL273419A (en) | Dosing regimen of siponimod | |
IL280515A (en) | Dosing regimens for elagolix | |
IL273382A (en) | Dosing regimen of siponimod | |
IL264139A (en) | Dosage regimens of lingo-1 antagonists and uses for treatment of demyelinating disorders | |
IL264243B (en) | Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage | |
SG10201912141YA (en) | Novel dosing regimens of celgosivir for the prevention of dengue | |
IL252903A0 (en) | Cgrp antagonist peptides | |
GB201614179D0 (en) | Dosage regimen for the treatment of endometriosis | |
GB201720541D0 (en) | Dosage regime | |
GB201720543D0 (en) | Dosage regime | |
GB201720542D0 (en) | Dosage regime | |
ZA201704249B (en) | Cgrp antagonist peptides | |
GB201710493D0 (en) | Dosage regime | |
GB201710496D0 (en) | Dosage regime |